tocacco plant Native American Tobaccoo flower, leaves, and buds

tocacco Tobacco is an annual or bi-annual growing 1-3 meters tall with large sticky leaves that contain nicotine. Native to the Americas, tobacco has a long history of use as a shamanic inebriant and stimulant. It is extremely popular and well-known for its addictive potential.

tocacco nicotina Nicotiana tabacum

tocacco Nicotiana rustica leaves. Nicotiana rustica leaves have a nicotine content as high as 9%, whereas Nicotiana tabacum (common tobacco) leaves contain about 1 to 3%

tocacco cigar A cigar is a tightly rolled bundle of dried and fermented tobacco which is ignited so that its smoke may be drawn into the mouth. Cigar tobacco is grown in significant quantities in Brazil, Cameroon, Cuba, Dominican Republic, Honduras, Indonesia, Mexico, Nicaragua, Sumatra, Philippines, and the Eastern United States.

tocacco Tobacco is an agricultural product processed from the fresh leaves of plants in the genus Nicotiana. It can be consumed, used as an organic pesticide, and in the form of nicotine tartrate it is used in some medicines. In consumption it may be in the form of cigarettes smoking, snuffing, chewing, dipping tobacco, or snus.

tocacco Cigarettes are smoking products consumed by people and made out of cut tobacco leaves. Cigars are typically composed completely of whole-leaf tobacco. A cigarette has smaller size, composed of processed leaf, and white paper wrapping. The term cigarette refers to a tobacco cigarette too but it can apply to similar devices containing other herbs, such as cannabis.
Tobacco-Facts ads

Genetically modified tobacco plants to fight HIV?

Drug companies have long used plants to produce pharmaceuticals-and tobacco plants, perhaps ironically, have been explored for Planta tobaccotheir potential role in fighting such things as cancer, cavities, scorpion venom, and more.

The latest big news, announced at a press conference in London this morning, is that U.K. regulators have, for the first time, approved a human clinical trial of a monoclonal antibody produced using genetically modified tobacco plants.

Monoclonal antibodies are made from identical immune cells that have been cloned from a unique parent cell to fulfill a specific role. The roots of this idea, which date back more than 100 years, helped German scientist Paul Ehrlich win a Nobel Prize in 1908 for work that ultimately resulted in an effective syphilis treatment.

But using tobacco plants that have been modified to stop the transmission of HIV is the culmination of a major 21st century project called Pharma-Planta, which was launched by a few dozen academic and industrial partners in 2004 with $17 million in funding from the European Union.

This initial trial in 11 participants will test the safety of the antibody, called P2G12, which is applied topically to the vaginal cavity and is thus specific to transmission to females. If it is proven to be safe, it will then be tested for effectiveness.

“This is a red-letter day for the field,” Julian Ma, scientific coordinator for Pharma-Planta and professor of molecular immunology at St George’s University of London, said in a statement. “The approval…is an acknowledgment that monoclonal antibodies can be made in plants to the same quality as those made using existing conventional production systems. That is something many people did not believe could be achieved.”

Although the plants were grown in containment greenhouses by the Fraunhofer Institute for Molecular Biology and Applied Ecology in Germany, the consortium says one of the major advantages of using genetically modified plants to derive antibodies is that they can be grown in the very country that needs them, a boon for both the environment and local economies.

Such a boon could, of course, be a long way off. Fraunhofer custom-designed its processing plant to isolate and purify P2G12, a step that was both expensive and groundbreaking. In fact, the facility was the first of its kind to be granted a license to manufacture recombinant pharmaceutical products from plants in Europe.

Ultimately, the approval of clinical trials of P2G12 opens the door for trials of other plant-derived medicines that could treat a wide range of diseases.

By Elizabeth Armstrong Moore

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • Technorati
  • StumbleUpon
  • Google Bookmarks
  • MySpace
  • MyShare
  • RSS
  • Twitter
  • Simpy
  • Sphinn
  • Yahoo! Buzz
  • Blogosphere News
  • Mixx
  • Reddit
  • Propeller
  • MisterWong
  • LinkedIn
Tobacco-Facts ads
discount cigarettes

Leave a Reply

 

 

 

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

*
To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word